412 related articles for article (PubMed ID: 24805108)
1. Endothelin and endothelin antagonists in chronic kidney disease.
Kohan DE; Barton M
Kidney Int; 2014 Nov; 86(5):896-904. PubMed ID: 24805108
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of endothelin receptor antagonism in kidney disease.
Czopek A; Moorhouse R; Webb DJ; Dhaun N
Am J Physiol Regul Integr Comp Physiol; 2016 Mar; 310(5):R388-97. PubMed ID: 26702154
[TBL] [Abstract][Full Text] [Related]
3. Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition.
Benigni A; Buelli S; Kohan DE
Pediatr Nephrol; 2021 Apr; 36(4):763-775. PubMed ID: 32185491
[TBL] [Abstract][Full Text] [Related]
4. Endothelin Receptor Antagonists: New Hope for Renal Protection?
Tobe S; Kohan DE; Singarayer R
Curr Hypertens Rep; 2015 Jul; 17(7):57. PubMed ID: 26068660
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease.
Komers R; Plotkin H
Am J Physiol Regul Integr Comp Physiol; 2016 May; 310(10):R877-84. PubMed ID: 27009050
[TBL] [Abstract][Full Text] [Related]
6. Endothelin in nondiabetic chronic kidney disease: preclinical and clinical studies.
Culshaw GJ; MacIntyre IM; Dhaun N; Webb DJ
Semin Nephrol; 2015 Mar; 35(2):176-87. PubMed ID: 25966349
[TBL] [Abstract][Full Text] [Related]
7. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.
Kohan DE; Pollock DM
Br J Clin Pharmacol; 2013 Oct; 76(4):573-9. PubMed ID: 23228194
[TBL] [Abstract][Full Text] [Related]
8. The endothelin system and endothelin receptor antagonists.
Jandeleit-Dahm KA; Watson AM
Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):66-71. PubMed ID: 22123210
[TBL] [Abstract][Full Text] [Related]
9. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
Correale M; Ferraretti A; Monaco I; Grazioli D; Di Biase M; Brunetti ND
Vasc Health Risk Manag; 2018; 14():253-264. PubMed ID: 30323613
[TBL] [Abstract][Full Text] [Related]
10. Renoprotective effects of ET(A) receptor antagonists therapy in experimental non-diabetic chronic kidney disease: Is there still hope for the future?
Vaněčková I; Hojná S; Kadlecová M; Vernerová Z; Kopkan L; Červenka L; Zicha J
Physiol Res; 2018 Jun; 67(Suppl 1):S55-S67. PubMed ID: 29947528
[TBL] [Abstract][Full Text] [Related]
11. A dual blocker of endothelin A/B receptors mitigates hypertension but not renal dysfunction in a rat model of chronic kidney disease and sleep apnea.
Morales-Loredo H; Jones D; Barrera A; Mendiola PJ; Garcia J; Pace C; Murphy M; Kanagy NL; Gonzalez Bosc LV
Am J Physiol Renal Physiol; 2019 May; 316(5):F1041-F1052. PubMed ID: 30810064
[TBL] [Abstract][Full Text] [Related]
12. Endothelin Blockade in Diabetic Kidney Disease.
Anguiano L; Riera M; Pascual J; Soler MJ
J Clin Med; 2015 May; 4(6):1171-92. PubMed ID: 26239552
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
[TBL] [Abstract][Full Text] [Related]
14. Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?
Chung EYM; Badve SV; Heerspink HJL; Wong MG
Nephrology (Carlton); 2023 Feb; 28(2):97-108. PubMed ID: 36350038
[TBL] [Abstract][Full Text] [Related]
15. Endothelin antagonism in patients with nondiabetic chronic kidney disease.
Dhaun N; Goddard J; Webb DJ
Contrib Nephrol; 2011; 172():243-254. PubMed ID: 21894004
[TBL] [Abstract][Full Text] [Related]
16. The endothelin system and its antagonism in chronic kidney disease.
Dhaun N; Goddard J; Webb DJ
J Am Soc Nephrol; 2006 Apr; 17(4):943-55. PubMed ID: 16540557
[TBL] [Abstract][Full Text] [Related]
17. Endothelin antagonism for patients with chronic kidney disease: still a hope for the future.
Schneider MP; Mann JF
Nephrol Dial Transplant; 2014 Feb; 29 Suppl 1():i69-i73. PubMed ID: 24493872
[TBL] [Abstract][Full Text] [Related]
18. Different roles of two types of endothelin receptors in partial ablation-induced chronic renal failure in rats.
Shimizu T; Hata S; Kuroda T; Mihara S; Fujimoto M
Eur J Pharmacol; 1999 Sep; 381(1):39-49. PubMed ID: 10528132
[TBL] [Abstract][Full Text] [Related]
19. Addition of ET(A) receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats.
Čertíková Chábová V; Vernerová Z; Kujal P; Husková Z; Škaroupková P; Tesař V; Kramer HJ; Kompanowska-Jezierska E; Walkowska A; Sadowski J; Červenka L; Vaněčková I
Life Sci; 2014 Nov; 118(2):297-305. PubMed ID: 24373834
[TBL] [Abstract][Full Text] [Related]
20. Renin-angiotensin system blockade alone or combined with ET
Sedláková L; Čertíková Chábová V; Doleželová Š; Škaroupková P; Kopkan L; Husková Z; Červenková L; Kikerlová S; Vaněčková I; Sadowski J; Kompanowska-Jezierska E; Kujal P; Kramer HJ; Červenka L
Clin Exp Hypertens; 2017; 39(2):183-195. PubMed ID: 28287881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
